Anti-osteoporotic treatments in neurological diseases

Giannini, Sandro (2009) Anti-osteoporotic treatments in neurological diseases. Functional Neurology; New Trends in Interventional Neurosciences, 24 (1). pp. 41-44. ISSN 1971-3274

PDF portiere.pdf - Published Version Restricted to Repository staff only Download (504kB)

Abstract

The constant ageing of the population has resulted in an increase in chronic conditions such as osteoporosis and neurodegenerative diseases as well as in patient comorbidity. Prolonged immobility, the use of osteopoenia-inducing drugs and an increased risk of falls in patients with neurological diseases have led to an increase in the incidence of fragility fractures, especially of the femur, in these patients. The consequences of these events are often dramatic, being associated with increased mortality, disability and worsening of cognitive and relational functions Potent drugs are currently available that can reduce fracture risk by up to 50% with long-term safety and tolerability. Bisphosphonates are the agents most extensively used to prevent fragility fractures. Risedronate has been demonstrated to reduce fracture risk, also in patients with neurological conditions. Considering that osteoporosis requires chronic treatment, patient compliance is extremely important to obtain treatment efficacy

Item Type:	Article
Uncontrolled Keywords:	Bisphosphonates, fall risk, fragility fractures, immobility, osteoporosis
Subjects:	600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 616 Malattie (classificare qui la Clinica medica, la medicina basata sull'evidenza, la Medicina interna, la Medicina sperimentale) > 616.7 Malattie del sistema muscoloscheletrico > 616.71 Malattie delle ossa > 616.716 Disturbi e patologie di origine metabolica (Classificare qui l’Osteoporosi) 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 616 Malattie (classificare qui la Clinica medica, la medicina basata sull'evidenza, la Medicina interna, la Medicina sperimentale) > 616.7 Malattie del sistema muscoloscheletrico > 616.71 Malattie delle ossa > 616.716 Disturbi e patologie di origine metabolica (Classificare qui l’Osteoporosi) > 616.71606 Disturbi e patologie di origine metabolica – Terapie 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 616 Malattie (classificare qui la Clinica medica, la medicina basata sull'evidenza, la Medicina interna, la Medicina sperimentale) > 616.8 Malattie del sistema nervoso e disturbi mentali (Classificare qui la Neuropsichiatria, la Neurologia) 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 616 Malattie (classificare qui la Clinica medica, la medicina basata sull'evidenza, la Medicina interna, la Medicina sperimentale) > 616.8 Malattie del sistema nervoso e disturbi mentali (Classificare qui la Neuropsichiatria, la Neurologia) > 616.85 Malattie varie del sistema nervoso e disturbi mentali di diverso genere > 616.858 Disturbi della personalità, sessuali, dell’identità di genere, del controllo degli impulsi, fittizi, dello sviluppo, dell’apprendimento; comportamento violento, ritardo mentale > 616.8588 Ritardo mentale; disturbi dello sviluppo e dell’apprendimento (Classificare qui i disturbi mentali solitamente diagnosticati in primo luogo nell’infanzia, nell’adolescenza) > 616.85889 Disturbi dell’apprendimento (Classificare qui i disturbi dell’apprendimento causati da disturbi genetici)
Depositing User:	Danilo Dezzi
Date Deposited:	04 Jul 2012 15:15
Last Modified:	04 Jul 2012 15:15
URI:	http://eprints.bice.rm.cnr.it/id/eprint/3593

Actions (login required)

View Item